GSK plc announced positive results from phase 3 trials for depemokimab in treating chronic rhinosinusitis with nasal polyps. The trials met primary endpoints, showing efficacy and safety in reducing polyp size and nasal obstruction.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing